These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9221559)

  • 1. [Interferon-alpha in the treatment of patients with chronic myeloid leukemia].
    Faber E; Jarosová M; Divoký V; Luhový M; Komenda S; Sulovská I; Hubácek J; Slezák P; Papajik T; Raida L; Heczko M; Indrák K
    Vnitr Lek; 1997 Jan; 43(1):13-7. PubMed ID: 9221559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia].
    Klamová H; Vítek A; Michalová K; Brezinová J; Moravcová J; Jelínek J; Cermák J
    Cas Lek Cesk; 1998 Sep; 137(18):552-6. PubMed ID: 9818464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alpha-interferons in the treatment of patients with chronic myeloid leukemia].
    Abdulkadyrov KM; Udal'eva VIu; Rukavitsyn OA; Bessmel'tsev SS
    Vopr Onkol; 1999; 45(4):387-92. PubMed ID: 10532097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
    Farag SS; Ruppert AS; Mrózek K; Carroll AJ; Pettenati MJ; Le Beau MM; Peterson BL; Powell BL; Ozer H; Silver RT; Larson RA; Bloomfield CD;
    Int J Oncol; 2004 Jul; 25(1):143-51. PubMed ID: 15201999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hematologic and cytogenetic response to treatment in patients with chronic myeloid leukemia].
    Tóthová E; Fricová M; Stecová N; Kafková A; Mudronová B; Svorcová E; Guman T; Raffac S; Hlebasková M
    Cas Lek Cesk; 2000 Jul; 139(14):437-9. PubMed ID: 11048406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
    Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
    Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic myeloid leukemia].
    Hehlmann R
    Ther Umsch; 1996 Feb; 53(2):82-7. PubMed ID: 8629268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Busulfan versus busulfan-interferon as maintenance therapy in chronic myeloid leukemia].
    López Hernández MA; Flores-Chapa JD; Trueba Christy E; Borbolla Escoboza JR; Carrillo Rosales T
    Rev Invest Clin; 1996; 48(4):281-7. PubMed ID: 8966391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
    Kantarjian HM; O'Brien S; Cortes JE; Shan J; Giles FJ; Rios MB; Faderl SH; Wierda WG; Ferrajoli A; Verstovsek S; Keating MJ; Freireich EJ; Talpaz M
    Cancer; 2003 Feb; 97(4):1033-41. PubMed ID: 12569603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
    Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D
    Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular biology follow-up of interferon therapy in patients with chronic myeloid leukemia].
    Iványi JL; Marton E; Kereskai L; Kiss Z; Pajor L
    Orv Hetil; 2000 Nov; 141(47):2527-33. PubMed ID: 11143285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The analysis of failures in the treatment of children with chronic myelocytic leukemia in the studies of Polish pediatric leukemia/ lymphoma group].
    Chybicka A; Bogusławska-Jaworska J; Kałwak K; Turkiewicz D; Armata J; Balcerska A; Cwiklińska M; Hicke-Roberts A; Kaczmarek-Kanold M; Kołecki P; Kowalczyk J; Krauze A; Matysiak M; Płoszyńska A; Rokicka-Milewska R; Sońta-Jakimczyk D; Sikorska-Fic B; Wiśniewska-Slusarz H; Wysocki M; Wachowiak J
    Wiad Lek; 1998; 51 Suppl 4():33-9. PubMed ID: 10731941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.